In conclusion, the low risk of systemic hypoglycemia and a better CNS absorption has prompted researchers to study the use of intranasal insulin therapy in the treatment of cognitive disorders such as Alzheimer's instead of the commonly used subcutaneous route or an IV route. This evidence concerns the gene INS and Cognitive impairment.